摘要:
Embodiments of the present invention relates to compounds labeled with imaging agents that also are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1). The labeled compounds are useful for the diagnosis and monitoring of diseases in which inflammation plays a role, such as various cardiovascular diseases including but not limited to atherosclerosis, vulnerable plaque, and coronary artery disease, as well as rheumatoid arthritis.
摘要:
A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target or a biomarker produced by or associated with the target. The protein is substantially free of a cofactor. Also disclosed are methods of administering the pretargeting species and the active-agent labeled species to a subject for diagnosing or treating a disease condition, or assessing the effectiveness of a treatment of the disease condition.
摘要:
The present invention relates to the use of Heat Shock Proteins and fragments thereof as targeting ligand. The Heat Shock Protein may be labeled with imaging agents that are capable of binding lectin-like oxidized low-density lipoprotein (LOX-1) or may be attached to a therapeutic agent. The sequences are useful for the diagnosis and monitoring of diseases as well as means for internalizing signaling moieties and therapeutics.
摘要:
In some embodiments, the present invention is directed to novel targeted contrast agents for magnetic resonance imaging (MRI). The present invention is also directed to methods of making such targeted MRI contrast agents, and to methods of using such MRI contrast agents. Typically, such targeted MRI contrast agents provide enhanced relaxivity, improved signal-to-noise, targeting ability, and resistance to agglomeration. Methods of making such MRI contrast agents typically afford better control over particle size, and methods of using such MRI contrast agents typically afford enhanced blood clearance rates and biodistribution.
摘要:
A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target or a biomarker produced by or associated with the target. The protein and the ligand are covalently attached. Also disclosed are methods of administering the pretargeting species and the active-agent labeled species to a subject for diagnosing or treating a disease condition, or assessing the effectiveness of a treatment of the disease condition.
摘要:
The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites.
摘要:
The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites.
摘要:
The present invention is generally directed to core/shell nanoparticles, wherein such core/shell nanoparticles comprise a nanoparticle core and a nanoshell disposed about the nanoparticle core such that, in the aggregate, they form a core/shell nanoparticle that is operable for use as an imaging agent in X-ray/computed tomography (CT). Typically, such core/shell nanoparticle-based X-ray CT imaging agents further comprise a targeting species for targeting the imaging agent to diseased sites.
摘要:
A cationic nanoparticle having an inorganic core and at least one outer cationic coating is described. The at least one outer cationic coating substantially covers the inorganic core and has at least one organo-silane. The organo-silane includes: —Si(R1)3 wherein R1independently at each occurrence is an alkoxy group, a hydroxyl group, a halide, an alkyl group, or hydrogen, and wherein at least one R1 of the three R1s is not an alkyl group. A nanocomplex having a cationic nanoparticle and at least one oligonucleotide attached to the cationic nanoparticle is also described. Methods of making cationic nanoparticles and nanocomplexes are also described. Also described are methods of delivering an oligonucleotide into a cell in-vitro, to a subject in-vivo, and monitoring the delivery of an oligonucleotide.
摘要:
The present technique provides for the analysis of a data series to identify sequences of interest within the series. The analysis may be used to iteratively update a grammar used to analyze the data series or updated versions of the data series. Furthermore, the technique provides for the calculation of a minimum description length heuristic, such as a symbol compression ratio, for each sub-sequence of the analyzed data sequence. The technique may then compare a selected heuristic value against one or more reference conditions to determine if additional iteration is to be performed. The grammar and the data sequence may be updated between iterations to include a symbol representing a string corresponding to the selected heuristic value based upon a non-termination result of the comparison. Alternatively, the string corresponding to the selected heuristic value may be identified as a sequence of interest based upon a termination result of the comparison.